{"_canonicalization":{"envelope_id":"axm_ + sha256(envelope minus {signature, axiom_id, anchors})","envelope_signature":"ed25519(envelope minus {signature, axiom_id})","json":"sort_keys=True, separators=(',',':'), ensure_ascii=False, allow_nan=False, utf-8","leaf_hash":"sha256(0x00 || canonical_json(envelope_full))","seal_signature":"ed25519(seal minus {signature, sig_algorithm})"},"axiom_id":"axm_2db0398d0a03d7a707a09fe44994c8d9e51805121b47a040b327ebcd55160220","bitcoin_anchor":{"bitcoin_attestations":[],"calendar_attestations":[],"ots_url":"","stamped_at":"","status":"pending_next_stamp"},"envelope":{"anchors":[{"chain":"crovia.axiom_graph","height":0,"merkle_proof":"spider_vendor_press_v1","root_at_anchor":"spider_vendor_press_v1"}],"axiom_id":"axm_2db0398d0a03d7a707a09fe44994c8d9e51805121b47a040b327ebcd55160220","axiom_type":"AX.OBS","body":{"axiom_subtype":"news.vendor_press.v1","category":"news","fingerprint":"075804f2b66837dde606755221e3955eb16d79071b6cb097a300fc8dc1946127","published":"Tue, 26 May 2026 00:00:00 -0400","receipt_hash":"075804f2b66837dde606755221e3955eb16d79071b6cb097a300fc8dc1946127","schema":"spider.news.vendor_press.v1","spider":"vendor_press","spider_record":{"axiom_subtype":"news.vendor_press.v1","category":"news","decision_hint":"POSITIVE","envelope_target":"AX.OBS","fingerprint":"075804f2b66837dde606755221e3955eb16d79071b6cb097a300fc8dc1946127","observed_at":"2026-05-26T04:43:39.018238Z","parent_run_hash":"dca8dedd754ad6a1772113d6b97ee4f4ab9a0afbdeb44aaace5ff2d2446b164b","published":"Tue, 26 May 2026 00:00:00 -0400","runtime_version":"0.1.0","schema":"spider.news.vendor_press.v1","source_status":200,"source_url":"https://export.arxiv.org/rss/cs.AI","spider":"vendor_press","summary_excerpt":"arXiv:2605.25250v1 Announce Type: new \nAbstract: Lipid nanoparticles (LNPs) are among the most clinically mature platforms for nucleic acid delivery, yet designing lipids that are both effective and biologically safe remains a major bottleneck. In practical screening, toxicity is a decision-level constraint: if a lipid is toxic, its efficiency prediction is clinically irrelevant. We propose LipoAgent, a safety-aware multi-agent LLM framework for lipid discovery. LipoAgent combines domain-specific finetuning with a conditional prediction objective that enforces toxicity as a prerequisite for efficiency prediction, and further improves reliability via multi-agent verification with lightweight human oversight when disagreement persists. Across multiple foundation models, LipoAgent achieves an average 32% relative improvement in mRNA transfection efficiency prediction compared with other reported models for lipid design. Wet-lab validation confirms that virtual screening rankings reliably ","title":"LipoAgent: Coordinating Fine-Tuned LLM Agents for Safer Lipid Design","url":"https://arxiv.org/abs/2605.25250","vendor":"arxiv_cs_ai"},"summary":"arXiv:2605.25250v1 Announce Type: new \nAbstract: Lipid nanoparticles (LNPs) are among the most clinically mature platforms for nucleic acid delivery, yet designing lipids that are both effective and biologically safe remains a major bottleneck. In practical screening, toxicity is a decision-level constraint: if a lipid is toxic, its efficiency prediction is clinically irrelevant. We propose LipoAgent, a safety-aware multi-agent LLM framework for lipid discovery. LipoAgent combines domain-specific finetuning with a conditional prediction objective that enforces toxicity as a prerequisite for efficiency prediction, and further improves reliability via multi-agent verification with lightweight human oversight when disagreement persists. Across multiple foundation models, LipoAgent achieves an average 32% relative improvement in mRNA transfection efficiency prediction compared with other reported models for lipid design. Wet-lab validation confirms that virtual screening rankings reliably ","title":"LipoAgent: Coordinating Fine-Tuned LLM Agents for Safer Lipid Design","vendor":"arxiv_cs_ai"},"confidence":{"method":"deterministic"},"decision":"POSITIVE","issued_at":"2026-05-26T04:43:39Z","notes":"Spider vendor_press (news) news.vendor_press.v1","object":{"captured_by":"crovia.spider.vendor_press","primary_source_url":"https://arxiv.org/abs/2605.25250"},"predecessors":[],"schema":"crovia.axiom.v1","signature":"ed25519:5f46ef848338e6b95ef6780a2c824c457fed96b67839ae6fcaad6279eec0a5ef83fc5fae5f291b6adf955c993510ce120ef511b39b0c56ae9e7ca0cbd6d61402","signer":"crovia.substrate","subject":{"observed_at":"2026-05-26T04:43:39Z","source_collector":"spider:vendor_press","target_id":"https://arxiv.org/abs/2605.25250"},"tsa":{"authority":"crovia.substrate.bootstrap","rfc3161_token":"{\"kind\":\"crovia.bootstrap.tsa\",\"source_jsonl\":\"/opt/crovia/spider/data/news/vendor_press_v1.jsonl\",\"source_seal_merkle_root\":\"spider_vendor_press_v1\",\"upgrade_path\":\"Sessione H \\u2014 OpenTimestamps weekly anchor\"}"},"zk_mode":"clear","zk_proof":null},"ledger":{"leaf_hash":"1cdf02f6ab7c4aa3105ba15e3b2678a2e4d48951e1b7fe1bbeaebe6067eb89a3","leaf_index":151412,"ledger_path":"/opt/crovia/substrate/axiom_ledger.jsonl"},"merkle_proof":{"hash_alg":"sha256","leaf_prefix":"0x00","node_prefix":"0x01","odd_leaf_rule":"duplicate_last","path":[{"sibling":"4c43ead6913092f96e2ed733a66e6cf0d778210a28be94fcaa6b8690f2e2daac","side":"right"},{"sibling":"5aa2e6c24f2a18d814a631766b6eef41508958ac7e1fc1395db54fe488adea9a","side":"right"},{"sibling":"fe1395ab24fbf8c5d6bdac12a04681ecdf9c2c4feee7bde948a90ea0b6819c36","side":"left"},{"sibling":"41373a52ae029af9e2cb8194678700c226e52967c325f19cf4194bc875b0d42d","side":"right"},{"sibling":"61b60b9ed13411c54bb7aa36d7438f81a2fa94381c764565f6c27b17e4c5ee38","side":"left"},{"sibling":"ccb0d1ce6fe03ae447d77b1a5d403df935110ea0f0cacdaa2f110858f5bf0ce1","side":"left"},{"sibling":"0a5010458437ccad9c345d7808e550a19558e3d8585ebb9302d9493157ff7a12","side":"left"},{"sibling":"8d693959d4763b28b351e1bc64d35b03213077740e93193dee0f2ab1f6459eb7","side":"right"},{"sibling":"a808644c9a09dd75253c6c0ba9275dc94a6b6451ad5184ebdafda4a2722b36a5","side":"left"},{"sibling":"fdd22ebd87e5ba37d1153e47753a63818abb25df8fe45dbf735ba5c512c3355b","side":"left"},{"sibling":"cf593c482d17d202b94914915d0c65fb8713053548db64771d0ec5dbb404a07f","side":"left"},{"sibling":"134949308b15cffd6792ee2cf678119af34d69a64764d7c89cd47573c94e1cda","side":"left"},{"sibling":"e20a7391fed5b5f3b675af68344a3f5b050d6701e127b7db010af3941e59dfdb","side":"right"},{"sibling":"e5893793e3591ed7f5e58ca94ffcfba46bb30f69fb1c25d5ba8ef49eb99f9126","side":"right"},{"sibling":"35ca36cee447f0ef7064a25d55f59357c66901e31427729c4c1d8b14aa8adb6c","side":"left"},{"sibling":"e3eecaf996dbe7229a7bb1d234c97aea97a252c5f7c89f8547b6d091db0f0e40","side":"right"},{"sibling":"55bcbd4da3e20d93931f7e58673f10232e81a5b1514d7396cb4b71e8f95788d0","side":"right"},{"sibling":"d841ad93efda0869e5eb97678f348f03f5caab4353e05ff4bf18f47fb945b822","side":"left"}]},"schema":"crovia.axiom_proof.v1","seal":{"first_collector_run_id":"","first_receipt_hash":"","jsonl_path":"/opt/crovia/substrate/axiom_ledger.jsonl","key_id":"430895f101d38164","last_collector_run_id":"","last_receipt_hash":"","leaf_count":152106,"merkle_root":"ac5182c6f3dd09931f2a689df5f4be36df7b55e55bcf106e195671f5ed55fd8f","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","run_id":"hourly_json_retrofit_20260526T053701Z","schema":"crovia.seal.v1","seal_family_version":"crovia-seal-family/1","seal_kind":"substrate_batch","sealed_at":"2026-05-26T05:37:34Z","sig_algorithm":"ed25519","signature":"a401243fbd2c077d29a623c6ef616c78fbd5c8ce1930afa7af7165b2386e5a8cf15d5094983a1c962e71b27b911a3f3ce09c8cfab9393be2ce5ce8ee6513da06","signer_version":"1.1.0"},"trust_root":{"key_id":"430895f101d38164","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","signature_algorithm":"ed25519","url":"/registry/canon/TRUST_ROOT.md"},"verifier":{"spec":"/registry/canon/AXIOM_RECEIPT_v1.md","url":"/v/axm_2db0398d0a03d7a707a09fe44994c8d9e51805121b47a040b327ebcd55160220"}}